Tracer validation for non [18F]FDG PET pharmaceuticals in automatic injector

被引：0
|
作者：
Hammar, M. [1 ]
Solem, R. [2 ]
Centofanti, F. Mörnsjö [2 ]
Evetovic, E. [2 ]
Akbari, A. [1 ]
Benner, K. [2 ]
Olsson, B. [1 ]
Holjer, E. [2 ]
Oddstig, J. [2 ]
机构：
[1] Skane Univ Hosp, Malmo, Sweden
[2] Skane Univ Hosp, Lund, Sweden
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-499
引用
收藏
页码：S227 / S227
页数：1
相关论文
共 50 条
  • [1] Robustness of radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR
    Vuong, D.
    Bogowicz, M.
    Huellner, M.
    Veit-Haibach, P.
    Andratschke, N.
    Unkelbach, J.
    Guckenberger, M.
    Tanadini-Lang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S41 - S41
  • [2] Synthesis and preliminary validation of 6-[18F]-Fluorodopamine ([18F]FDA) as a PET tracer for neuroblastoma
    Vavere, Amy
    Butch, Elizabeth
    Shulkin, Barry
    Snyder, Scott
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [3] Non-[18F]FDG PET in clinical oncology
    Groves, Ashley M.
    Win, Thida
    Ben Haim, Simona
    Ell, Peter J.
    LANCET ONCOLOGY, 2007, 8 (09): : 822 - 830
  • [4] [18F]FDG PET/CT outperforms [18F]FDG PET/MRI in differentiated thyroid cancer
    Vrachimis, Alexis
    Burg, Matthias Christian
    Wenning, Christian
    Allkemper, Thomas
    Weckesser, Matthias
    Schaefers, Michael
    Stegger, Lars
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (02) : 212 - 220
  • [5] [18F]FDG PET/CT outperforms [18F]FDG PET/MRI in differentiated thyroid cancer
    Alexis Vrachimis
    Matthias Christian Burg
    Christian Wenning
    Thomas Allkemper
    Matthias Weckesser
    Michael Schäfers
    Lars Stegger
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 212 - 220
  • [6] Robustness study on radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR
    Vuong, D.
    Bogowicz, M.
    Huellner, M.
    Veit-Haibach, P.
    Andratschke, N.
    Unkelbach, J.
    Guckenberger, M.
    Tanadini-Lang, S.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1159 - S1159
  • [7] Interchangeability of radiomic features between [18F]-FDG PET/CT and [18F]-FDG PET/MR
    Diem Vuong
    Tanadini-Lang, Stephanie
    Huellner, Martin W.
    Veit-Haibach, Patrick
    Unkelbach, Jan
    Andratschke, Nicolaus
    Kraft, Johannes
    Guckenberger, Matthias
    Bogowicz, Marta
    MEDICAL PHYSICS, 2019, 46 (04) : 1677 - 1685
  • [8] IN VITRO AND IN VIVO EVALUATION OF THE LAT1 PET TRACER 2-[18F]FELP IN COMPARISON TO [18F]FET AND [18F]FDG
    Verhoeven, J.
    Bolcaen, J.
    Kersemans, K.
    De Meulenaere, V.
    Deblaere, K.
    Kalala, J.
    Van den Broecke, C.
    Vanhove, C.
    Goethals, I.
    De Vos, F.
    NEURO-ONCOLOGY, 2017, 19 : 46 - 46
  • [9] Is 3′-deoxy-3′-[18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?
    Couturier, O
    Leost, F
    Campone, M
    Carlier, T
    Chatal, JF
    Hustinx, R
    BULLETIN DU CANCER, 2005, 92 (09) : 789 - 798
  • [10] Staging with [18F]FDG PET/CT
    Iqbal, Ramsha
    Aras, Tuba
    Mammatas, Lemonitsa
    Vogel, Wouter V.
    Oprea-Lager, Daniela E.
    Verheul, Hendrik M.
    Boellaard, Ronald
    van Oordt, Catharina W. Menke-van der Houven
    CANCER RESEARCH, 2019, 79 (13)
12345